Literature DB >> 25687550

Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.

M Rafiuddin Ahmed1, Evgeny Bychkov1, Seunghyi Kook1, Lilia Zurkovsky1, Kevin N Dalby2, Eugenia V Gurevich3.   

Abstract

l-DOPA therapy in Parkinson's disease often results in side effects such as l-DOPA-induced dyskinesia (LID). Our previous studies demonstrated that defective desensitization of dopamine receptors caused by decreased expression of G protein-coupled receptor kinases (GRKs) plays a role. Overexpression of GRK6, the isoform regulating dopamine receptors, in parkinsonian rats and monkeys alleviated LID and reduced LID-associated changes in gene expression. Here we show that 2-fold lentivirus-mediated overexpression of GRK6 in the dopamine-depleted striatum in rats unilaterally lesioned with 6-hydroxydopamine ameliorated supersensitive ERK response to l-DOPA challenge caused by loss of dopamine. A somewhat stronger effect of GRK6 was observed in drug-naïve than in chronically l-DOPA-treated animals. GRK6 reduced the responsiveness of p38 MAP kinase to l-DOPA challenge rendered supersensitive by dopamine depletion. The JNK MAP kinase was unaffected by loss of dopamine, chronic or acute l-DOPA, or GRK6. Overexpressed GRK6 suppressed enhanced activity of Akt in the lesioned striatum by reducing elevated phosphorylation at its major activating residue Thr(308). Finally, GRK6 reduced accumulation of ΔFosB in the lesioned striatum, the effect that paralleled a decrease in locomotor sensitization to l-DOPA in GRK6-expressing rats. The results suggest that elevated GRK6 facilitate desensitization of DA receptors, thereby normalizing of the activity of multiple signaling pathways implicated in LID. Thus, improving the regulation of dopamine receptor function via the desensitization mechanism could be an effective way of managing LID.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt; ERK1/2; GRK6; JNK; Lentivirus; Parkinson's disease; l-DOPA-induced dyskinesia; p38; ΔFosB

Mesh:

Substances:

Year:  2015        PMID: 25687550      PMCID: PMC4464750          DOI: 10.1016/j.expneurol.2015.02.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  82 in total

1.  Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Authors:  B Henry; S H Fox; A R Crossman; J M Brotchie
Journal:  Exp Neurol       Date:  2001-09       Impact factor: 5.330

2.  Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.

Authors:  Emanuela Santini; Emmanuel Valjent; Alessandro Usiello; Manolo Carta; Anders Borgkvist; Jean-Antoine Girault; Denis Hervé; Paul Greengard; Gilberto Fisone
Journal:  J Neurosci       Date:  2007-06-27       Impact factor: 6.167

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

4.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

5.  Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.

Authors:  Abigail M Brown; Ariel Y Deutch; Roger J Colbran
Journal:  Eur J Neurosci       Date:  2005-07       Impact factor: 3.386

6.  Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

Authors:  Céline Guigoni; Sandra Dovero; Incarnation Aubert; Qin Li; Bernard H Bioulac; Bertrand Bloch; Eugenia V Gurevich; Christian E Gross; Erwan Bezard
Journal:  Eur J Neurosci       Date:  2005-07       Impact factor: 3.386

7.  The structure of G protein-coupled receptor kinase (GRK)-6 defines a second lineage of GRKs.

Authors:  David T Lodowski; Valerie M Tesmer; Jeffrey L Benovic; John J G Tesmer
Journal:  J Biol Chem       Date:  2006-04-13       Impact factor: 5.157

8.  Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation.

Authors:  Mohamed Rafiuddin Ahmed; Vsevolod V Gurevich; Kevin N Dalby; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Pharmacol Exp Ther       Date:  2008-01-04       Impact factor: 4.030

9.  Doubly truncated FosB isoform (Delta2DeltaFosB) induces osteosclerosis in transgenic mice and modulates expression and phosphorylation of Smads in osteoblasts independent of intrinsic AP-1 activity.

Authors:  George Sabatakos; Glenn C Rowe; Marie Kveiborg; Meilin Wu; Lynn Neff; Riccardo Chiusaroli; William M Philbrick; Roland Baron
Journal:  J Bone Miner Res       Date:  2008-05       Impact factor: 6.741

10.  The origin and evolution of G protein-coupled receptor kinases.

Authors:  Arcady Mushegian; Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

View more
  9 in total

Review 1.  G Protein-Coupled Receptor Kinases in the Inflammatory Response and Signaling.

Authors:  Michael D Steury; Laura R McCabe; Narayanan Parameswaran
Journal:  Adv Immunol       Date:  2017-06-10       Impact factor: 3.543

Review 2.  G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Authors:  Eugenia V Gurevich; Raul R Gainetdinov; Vsevolod V Gurevich
Journal:  Pharmacol Res       Date:  2016-05-10       Impact factor: 7.658

3.  The lentiviral-mediated Nurr1 genetic engineering mesenchymal stem cells protect dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Xiaoxiao Wang; Wenxin Zhuang; Wenyu Fu; Xiaocui Wang; E Lv; Fengjie Li; Shuanhu Zhou; Wolf-Dieter Rausch; Xin Wang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

4.  GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain.

Authors:  Mohamed R Ahmed; Evgeny Bychkov; Lingyong Li; Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

Review 5.  GRKs as Modulators of Neurotransmitter Receptors.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Cells       Date:  2020-12-31       Impact factor: 6.600

6.  G protein-coupled receptor kinases are associated with Alzheimer's disease pathology.

Authors:  Thais Rafael Guimarães; Eric Swanson; Julia Kofler; Amantha Thathiah
Journal:  Neuropathol Appl Neurobiol       Date:  2021-07-19       Impact factor: 8.090

Review 7.  Current Experimental Studies of Gene Therapy in Parkinson's Disease.

Authors:  Jing-Ya Lin; Cheng-Long Xie; Su-Fang Zhang; Weien Yuan; Zhen-Guo Liu
Journal:  Front Aging Neurosci       Date:  2017-05-03       Impact factor: 5.750

8.  Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors.

Authors:  Jace Jones-Tabah; Hanan Mohammad; Shadi Hadj-Youssef; Lucy E H Kim; Ryan D Martin; Faïza Benaliouad; Jason C Tanny; Paul B S Clarke; Terence E Hébert
Journal:  Sci Rep       Date:  2020-09-02       Impact factor: 4.379

Review 9.  Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.

Authors:  Giada Spigolon; Gilberto Fisone
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.